Literature DB >> 17431772

Pharmacokinetics of cyclosporine A after massive hepatectomy: a hint for small-for-size graft in living donor liver transplantation.

Hisamitsu Shinohara1, Mitsuo Shimada, Takashi Ogasawara, Yuji Morine, Tetsuya Ikemoto, Satoru Imura, Masahiko Fujii.   

Abstract

In living donor liver transplantation, graft size is very important, and various studies have been conducted regarding these problems in small-for-size (SFS) grafts. The administration of immunosuppressants for SFS graft, in which the functional liver mass is small and necessary for excessive liver regeneration, has not been reported so far. The aims of this study were to investigate the optimal administration of cyclosporine (CyA) and characteristics of metabolism of CyA, according to liver volume. Seven-week-old male Wister rats were randomly divided into four groups: two CyA-administered groups (CyA groups), 70% and 90% hepatectomy (Hx); and two control groups, 70% and 90% Hx. The 70% Hx and 90% Hx were used as the surrogate model of SFS for 30% and 10% graft models. In CyA groups, CyA (5 mg/kg/day) was given for 3 days before Hx and after surgery until sacrifice. Animals were sacrificed at 0, 12, 24, 48, and 72 hr after Hx. The blood concentration of CyA and the expression of the CYP3A2 gene were measured at each point in CyA groups, and liver regeneration was evaluated by measuring the ratio of remnant liver weight to body weight in each group. Regarding the blood concentration of CyA, no difference was recognized between 30% and 10% graft models except for 72 hr after Hx. As for liver regeneration, no significant difference was recognized. Regarding the expression of CYP3A2, no change was noted in the 30% graft model; on the other hand, CYP3A2 expression was reduced. Significant differences between the 30% and the 10% graft model were observed 48 and 72 hr after Hx. The blood concentration of CyA was not dependent on the volume of the liver graft.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431772     DOI: 10.1007/s10620-007-9744-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Small-for-size grafts in living-related liver transplantation.

Authors:  Y Sugawara; M Makuuchi; T Takayama; H Imamura; S Dowaki; K Mizuta; H Kawarasaki; K Hashizume
Journal:  J Am Coll Surg       Date:  2001-04       Impact factor: 6.113

2.  Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs.

Authors:  U Dahmen; Y Gu; K Shen; O Dirsch; J Li; L Fan; C Broelsch
Journal:  Transplant Proc       Date:  2002-09       Impact factor: 1.066

3.  Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose.

Authors:  J Molpeceres; M Chacón; M Guzmán; M R Aberturas; L Berges
Journal:  Int J Pharm       Date:  2000-03-20       Impact factor: 5.875

4.  Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.

Authors:  Mingji Jin; Tsutomu Shimada; Miki Shintani; Koichi Yokogawa; Masaaki Nomura; Ken-Ichi Miyamoto
Journal:  Drug Metab Pharmacokinet       Date:  2005-10       Impact factor: 3.614

Review 5.  Alternative cyclosporine metabolic pathways and toxicity.

Authors:  U Christians; K F Sewing
Journal:  Clin Biochem       Date:  1995-12       Impact factor: 3.281

6.  Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.

Authors:  Koichi Yokogawa; Tsutomu Shimada; Yasuhiko Higashi; Yoshie Itoh; Toshiko Masue; Junko Ishizaki; Mariko Asahi; Ken-ichi Miyamoto
Journal:  Biochem Pharmacol       Date:  2002-02-15       Impact factor: 5.858

7.  Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8).

Authors:  D Grant; N Kneteman; J Tchervenkov; A Roy; G Murphy; A Tan; L Hendricks; N Guilbault; G Levy
Journal:  Transplantation       Date:  1999-04-27       Impact factor: 4.939

8.  Impact of graft size mismatching on graft prognosis in liver transplantation from living donors.

Authors:  T Kiuchi; M Kasahara; K Uryuhara; Y Inomata; S Uemoto; K Asonuma; H Egawa; S Fujita; M Hayashi; K Tanaka
Journal:  Transplantation       Date:  1999-01-27       Impact factor: 4.939

9.  Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing.

Authors:  Masahide Fukudo; Ikuko Yano; Satohiro Masuda; Toshiya Katsura; Yasuhiro Ogura; Fumitaka Oike; Yasutsugu Takada; Koichi Tanaka; Ken-Ichi Inui
Journal:  Liver Transpl       Date:  2006-02       Impact factor: 5.799

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more
  1 in total

1.  Optimal administration of tacrolimus in reduced-size liver.

Authors:  Yuji Morine; Mitsuo Shimada; Mayumi Torii; Satoru Imura; Toru Ikegami; Hirohumi Kanemura; Yusuke Arakawa; Jun Hanaoka; Mami Kanamoto; Akira Nii; Naoshi Yamazaki
Journal:  Dig Dis Sci       Date:  2008-11-12       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.